[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cesarean-section-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cesarean-section-complications":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,41,62,87,113,141,174,200,230,263,284,305,328,357,378,408,430],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100541060","analgesic-efficacy-of-surgeon-administered-transversus-abdominis-plane-blocks-for-caesarean-section-100541060",false,"NCT06324942","Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section.","Inclusion Criteria:\n\n* ASA status II to III\n* All patients undergoing elective CS under regional anesthesia at any gestational age.\n\nExclusion Criteria:\n\n* \\- Known drug allergy to local anesthetics\n* Planned general anesthetic\n* NSAID use contraindicated post partum\n* Chronic pain disorder or chronic narcotic use\u002Fdependence\n* Planned vertical abdominal incision\n* Planned Cesarean Hysterectomy.\n* Placenta Previa or suspected Placenta Accreta",true,"FEMALE","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital.",[26,27],"Cesarean Section Complications","Pain, Postoperative","RECRUITING","2026-06-10",{"date":31,"type":32},"2026-06-15","ACTUAL",{"date":34,"type":32},"2025-02-19",{"date":36,"type":20},"2026-12",{"name":38,"class":39},"University of Calgary","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":60,"locationsCount":40},"100542156","wound-irrigation-with-saline-versus-hypodilute-chlorhexidine-after-cesarean-section-wishes-study-100542156","NCT06339203","Wound Irrigation With Saline Versus Hypodilute-chlorhexidine After Cesarean Section (WISHES Study)","Wound Irrigation With Saline Versus Hypodilute-chlorhexidine After Cesarean Section: a Randomized Clinical Trial (WISHES Study)","Inclusion Criteria:\n\n* Age 18 or older\n* Singleton pregnancy\n* Planned cesarean delivery at gestational age 37 weeks or later at Loma Linda University Children's Hospital\n* Planned post-operative follow up with Loma Linda OBGYN\n* Speak English or Spanish\n* At least one of the following medical complications: Obesity BMI\\>= 30kg\u002Fm2, Diabetes, Spontaneous rupture of membranes, Intraamniotic infection\n\nExclusion Criteria:\n\n* Emergency cesarean delivery",{"count":49,"type":20},400,[23],"This investigator-initiated, open-label, randomized controlled trial will explore the effects of two treatment arms, comparing standard treatment with normal saline against Irrisept, a jet lavage solution containing a low concentration of Chlorhexidine Gluconate (CHG) at 0.05% in 99.95% sterile water for irrigation. The study aims to evaluate the impact on postoperative wound healing in patients who have undergone cesarean delivery.",[26,53],"Cesarean Section; Infection","2026-06-05",{"date":56,"type":32},"2026-06-08",{"date":58,"type":32},"2024-06-05",{"date":36,"type":20},{"name":61,"class":39},"Loma Linda University",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100468495","personalized-perioperative-analgesia-platform-ppap-for-cesarean-section-100468495","NCT05380531","Personalized Perioperative Analgesia Platform (PPAP) for Cesarean Section","PPAP C-Section","Inclusion Criteria:\n\nAdult women (\\>18 yr) All races American Society of Anesthesiologists Classification (ASA) physical status: 1 to 3 undergoing elective Cesarean section that are willing to receive in-patient opioids.\n\nExclusion Criteria:\n\n1. Health conditions including uncontrolled diabetes (gestational or pre-existing) or hypertension (pre-eclampsia, eclampsia, or chronic)\n2. Any history of opioid misuse before or during pregnancy-per self-report and clinical notes\n3. Preoperative severe pain and opioid use\u002Fmisuse, allergy to oxycodone\n4. Allergy to oxycodone\n5. Significant neurological disorders, liver and renal diseases",{"count":70,"type":20},700,[23],"The purpose of this collaborative CTSA (Clinical and Translational Science Award) application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in breastfeeding mothers and their infants",[26,74],"Opioid Use",[76],"Opioid Exposure","2026-04-08",{"date":79,"type":32},"2026-04-14",{"date":81,"type":32},"2022-12-05",{"date":83,"type":20},"2027-10-30",{"name":85,"class":39},"Senthil Sadhasivam",4,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100620679","ultrasonographic-onsd-as-a-predictor-of-pdph-in-spinal-anesthesia-for-cesarean-delivery-100620679","NCT07360756","Ultrasonographic ONSD as a Predictor of PDPH in Spinal Anesthesia for Cesarean Delivery","Early Prediction of Post-Dural Puncture Headache Using Ultrasound-Measured Optic Nerve Sheath Diameter in Cesarean Section Patients: A Prospective Observational Study","Inclusion Criteria:\n\n* Adult female patients, aged 18-45 years\n* ASA(American Society of Anesthesiologists) physical status II or III\n* Scheduled for elective cesarean section\n* Undergoing surgery under standardized spinal anesthesia\n\nExclusion Criteria:\n\n* Pre-existing headache disorders (e.g., migraine, chronic tension-type headache)\n* Known ophthalmic conditions (e.g., optic neuropathy, glaucoma)\n* Inability to cooperate with ONSD(Optic Nerve Sheath Diameter) ultrasound measurements or follow-up\n* Allergy to local anesthetics\n* Emergency cesarean section\n* Contraindications to spinal anesthesia:\n\n  * Coagulopathy\n  * Infection at the puncture site\n* Preexisting hypertension on medication\n* Pre-eclampsia with severe features (suggested for separate study)\n* Known cardiac disease with hemodynamic instability\n* Allergy to study drugs\n* Fetal distress or non-reassuring cardiotocography (CTG)\n* Body Mass Index (BMI) \\>40 kg\u002Fm²\n* Refusal to sign informed consent","45 Years",{"count":96,"type":20},150,"OBSERVATIONAL","The Optic Nerve Sheath Diameter (ONSD), measured non-invasively by bedside ultrasound, is a well-established surrogate for intracranial pressure (ICP), as the optic nerve sheath is continuous with the intracranial dura mater and its subarachnoid space is filled with cerebrospinal fluid (CSF). While ONSD is typically used to detect elevated ICP (with a cut-off often \\> 5.0-5.7 mm for ICP \\> 20 mmHg), studies investigating PDPH have paradoxically shown a reduction in ONSD post-spinal anesthesia, correlating with the state of intracranial hypotension.\n\nPrevious research has demonstrated that a lower ONSD or a significant decrease in ONSD values 24 hours post-puncture is associated with PDPH development. A study determined that an ONSD at 24 hours of less than 0.40 cm was the best predictor for PDPH. Our study aims to specifically investigate the utility of the immediate change in ONSD to offer a bedside, real-time assessment of risk.",[26],[101,102],"Post-Dural Puncture Headache","Optic Nerve Sheath Diameter","NOT_YET_RECRUITING","2026-01-17",{"date":106,"type":32},"2026-01-22",{"date":108,"type":20},"2026-01-28",{"date":110,"type":20},"2026-12-30",{"name":112,"class":39},"Al-Azhar University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":40},"100614318","trends-in-the-administration-of-tranexamic-acid-for-postpartum-hemorrhage-100614318","NCT07278037","Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage","A Retrospective Analysis of the Longitudinal Pattern of Tranexamic Acid Administration in Parturients Undergoing Cesarean Delivery Complicated by Postpartum Hemorrhage","Inclusion Criteria:\n\n* 1\\. Patients underwent cesarean delivery with primary postpartum hemorrhage\n\nExclusion Criteria:\n\n1. Gestational age at less than 24 weeks\n2. Absence of the anesthetic record\n3. Received tranexamic acid in the antepartum period\n4. Blood loss less than 1,000 ml",{"count":121,"type":20},648,"Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.",[124,125,26,126],"Postpartum Hemorrhage","Delivery Complication","Perinatal Problems",[128,129,130,131],"cesarean delivery","complications","postpartum hemorrhage","tranexamic acid","2025-12-16",{"date":134,"type":32},"2025-12-22",{"date":136,"type":32},"2025-12-01",{"date":138,"type":20},"2026-09-30",{"name":140,"class":39},"Mahidol University",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100476785","phase-2-oxytocin-pharmacokinetics-and-pharmacodynamics-100476785","NCT05488457","Oxytocin Pharmacokinetics and Pharmacodynamics","Pharmacokinetics and Pharmacodynamics of Oxytocin in Cesarean Delivery","Inclusion Criteria\n\n* 18-50 years old\n* intrauterine pregnancy\n* term (\\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy\n* non-emergent (scheduled or unscheduled) cesarean delivery\n\nExclusion Criteria:\n\n* allergy or contraindication to oxytocin\n* inability to provide informed consent","50 Years",{"count":150,"type":20},100,[152],"PHASE2","Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynamics of all plasma oxytocin to see how concentrations correspond to the contractile effect on the uterus.\n\nAfter delivery of the fetus, study subjects will receive a bolus of IV deuterated oxytocin followed by an unlabeled oxytocin infusion. Venous blood samples drawn at multiple time points (within 1 hour after delivery) will be analyzed for plasma concentrations of labeled and unlabeled (endogenous + exogenous infused) oxytocin over time. Plasma concentrations will be compared with 0-10 uterine tone scores measuring uterine contraction strength, to describe the concentration-effect relationship.\n\nThe goal of this study is to define both the pharmacokinetics and pharmacodynamics of oxytocin in parturients to help identify the cause(s) of failed first-line oxytocin therapy.",[155,26,156],"Post Partum Hemorrhage","Blood Loss",[158,159,160,161,162,163],"Oxytocin","pharmacokinetics and Pharmacodynamics","Uterine Tone","Postpartum","Elective C-Section","Parturients","2025-10-01",{"date":166,"type":32},"2025-10-03",{"date":168,"type":32},"2025-01-01",{"date":170,"type":20},"2027-12-31",{"name":172,"class":39},"University of Chicago",2,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":180,"maxAge":94,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":40},"100607049","combined-hystroscopic-and-laparoscopic-repair-of-cs-scar-disorder-100607049","NCT07183501","Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder","Inclusion Criteria:\n\n* symptomatic uterine Niche :postmenstrual spotting\n\nExclusion Criteria:\n\n* contraindications for endoscopy","20 Years",{"count":182,"type":20},30,[23],"Combined hystroscopic and laparoscopic repair of symptomatic uterine Niche as new technique to maximize resolution of symptoms after niche repair with concomitant increase in RMT",[26,186],"Abnormal Uterine Bleeding",[188,189,190],"Cesarean Section","niche","CSD","2025-09-17",{"date":193,"type":32},"2025-09-19",{"date":195,"type":32},"2024-06-01",{"date":197,"type":20},"2027-03-01",{"name":199,"class":39},"Assiut University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":173},"100535189","phase-4-continuous-infusion-of-norepinephrine-vs-phenylephrine-during-spinal-anesthesia-for-cesarean-section-inpeace-100535189","NCT06248593","Continuous Infusion of Norepinephrine vs Phenylephrine During Spinal Anesthesia for Cesarean Section (INPEACE)","Manually Controlled Continuous Infusion of Norepinephrine vs Phenylephrine During Spinal Anesthesia for Cesarean Section: A Double-blinded Randomized Controlled Study","INPEACE","Inclusion Criteria:\n\n* Full-term, singleton, pregnant women, nonlaboring.\n* Scheduled for elective cesarean delivery under spinal anesthesia,\n* American Society of Anesthesiologists physical status : 1 or 2\n* Baseline systolic BP between 90 and 140 mm Hg.\n\nExclusion Criteria:\n\n* Known fetal abnormality.\n* Preexisting or pregnancy-induced hypertension, cardiovascular, cerebrovascular or kidney disease.\n* Contraindication to spinal anesthesia.\n* Peripartum hemorrhage.\n* Body mass index above 40 kg\u002Fm2.",{"count":209,"type":20},140,[211],"PHASE4","The goal of this clinical trial is to compare norepinephrine and ephedrine in maintaining blood pressure during spinal anaesthesia for elective cesarean delivery. The main questions it aims to answer are:\n\n* Do phenylephrine and norepinephrine administered as manually controlled continuous infusion during elective cesarean delivery have different effects on neonatal outcome ?\n* Do phenylephrine and norepinephrine administered as manually controlled continuous infusion during elective cesarean delivery have different effects on maternal hemodynamics? Participants will receive either phenylephrine or norepinephrine infusion, at the time of performing spinal anesthesia, the infusion rate will be adjusted manually depending on maternal arterial pressure.",[26,214],"Hypotension",[216,217,128,218,219,220],"hypotension","norepinephrine","Obstetric anesthesia","Spinal anesthesia","Phenylephrine","2025-09-08",{"date":223,"type":32},"2025-09-09",{"date":225,"type":32},"2025-01-29",{"date":227,"type":20},"2026-03-15",{"name":229,"class":39},"Hassan II University",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":40},"100456525","platelet-rich-plasma-for-uterine-scar-100456525","NCT05224726","Platelet Rich Plasma for Uterine Scar","Platelet Rich Plasma for the Treatment of Uterine Scar","AA-PRP","Inclusion criteria:\n\n* Women undergoing elective cesarean delivery\n* Term pregnancy (≥37 weeks of gestation)\n\nExclusion criteria:\n\n* Thrombocytopenia (CBC Platelet count \\\u003C70,000)\n* Connective tissue disease\n* Uterine scars other than cesarean (s\u002Fp myomectomy, s\u002Fp cornual resection)\n* Malformed uterus (unicornuate, bicornuate, didelphic)","52 Years",{"count":240,"type":20},40,[23],"When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.",[26,244,245,246],"Uterine Bleeding","Pelvic Pain","Menstrual Irregularity",[248,128,249,250,189,251,252,253],"uterine scar defect","pelvic pain","spotting","cesarean section complication","uterine scar","Platelet Rich Plasma (PRP)","2025-08-24",{"date":256,"type":32},"2025-08-26",{"date":258,"type":32},"2025-07-19",{"date":260,"type":20},"2028-07-01",{"name":262,"class":39},"The University of Texas Health Science Center, Houston",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":269,"targetDuration":4,"studyType":21,"phases":271,"briefSummary":267,"conditions":272,"keywords":273,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":40},"100603755","phase-4-effect-of-a-20-reduction-in-hyperbaric-bupivacaine-dose-on-high-spinal-block-incidence-in-cesarean-delivery-a-risk-stratified-randomized-controlled-trial-100603755","NCT07140640","Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.","Inclusion Criteria:\n\n* • Pregnant women aged 18-45 years.\n\n  * ASA physical status II-III.\n\nExclusion Criteria:\n\n* • Twin pregnancies.\n\n  * Contraindications to spinal anesthesia (e.g., coagulopathy, infection).\n  * Patients with incomplete preoperative data for risk stratification.",{"count":270,"type":20},333,[211],[26],[274],"cesarean-20% hyperbaric bupivacaine","2025-08-22",{"date":277,"type":32},"2025-08-25",{"date":279,"type":20},"2025-09-15",{"date":281,"type":20},"2026-03-30",{"name":283,"class":39},"Aswan University",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100567512","insufficient-regional-anesthesia-and-conversion-to-general-anesthesia-for-cesarean-section-a-qualitative-multicenter-study-100567512","NCT06669156","Insufficient Regional Anesthesia and Conversion to General Anesthesia for Cesarean Section A Qualitative Multicenter Study","Inclusion Criteria:\n\n* Women undergoing elective or emergency cesarean section, aged over 17 years\n* Regional (spinal or epidural or combined epidural-spinal) anesthesia converted to general anesthesia intraoperatively (i.e., after surgery has commenced) due to insufficient regional anesthesia (i.e., not for obstetric indications, such as in cases of difficult fetal extraction)\n\nExclusion Criteria:\n\n* Does not speak Danish or English\n* Does not wish to participate",{"count":182,"type":20},"Background In Denmark, approximately 20% of all children are born via cesarean section (C-section), making it the most common surgical procedure (also internationally). The recommended anesthesia for cesarean sections is regional anesthesia (spinal or epidural, \"spinal anesthesia\"), as it has several advantages: the woman is awake and experiences the delivery of her child, she maintains spontaneous breathing (the risk of difficult airway management is significantly higher in pregnant women), and the risk of aspiration of stomach contents into the lungs (which is clearly increased in pregnant women) is reduced. Furthermore, regional anesthesia can contribute to early postoperative pain management to some extent.\n\nWith spinal anesthesia, most women feel pressure and touch but no pain during the cesarean section. However, some women do experience pain during the procedure, necessitating a change in the plan. If inadequate anesthesia is detected before the surgery begins, one may choose (depending on, for example, the urgency of the cesarean) to administer renewed regional anesthesia (typically an epidural). However, if the woman first experiences pain after the surgery has commenced, it is necessary to place her under general anesthesia for the remainder of the procedure. Experience shows that this process can be challenging, and there are frequent examples in clinical practice of inappropriate courses of action, where women have experienced unacceptable pain during their cesarean sections without being placed under general anesthesia. It is difficult to obtain an exact figure on how many women experience inadequate anesthesia during cesarean sections under regional anesthesia, as not all cases are recognized or followed up on. Studies indicate that up to 12% experience pain during a cesarean section.\n\nThe consequences of inadequate anesthesia for cesarean sections can be quite significant for women, including impaired bonding with the child, poorer establishment of breastfeeding, increased risk of postpartum reactions and post-traumatic stress, as well as (anecdotally) the risk of women opting out of future pregnancies, as they may be reluctant to subject themselves to a similar situation again.\n\nAim The aim of this study is to investigate how women experience insufficient regional anesthesia during cesarean sections that require conversion to general anesthesia. The focus is on exploring the factors that contribute positively and negatively to the woman's experience in this situation.\n\nMethod Qualitative study in six Danish hospitals.\n\nInclusion criteria:\n\n* Women undergoing elective or emergency cesarean section, aged over 17 years\n* Regional (spinal or epidural or combined epidural-spinal) anesthesia converted to general anesthesia intraoperatively (i.e., after surgery has commenced) due to insufficient regional anesthesia (i.e., not for obstetric indications, such as in cases of difficult fetal extraction)\n\nExclusion criteria:\n\n* Does not speak Danish or English\n* Does not wish to participate\n\nThe woman will be contacted for the first time on day 1 or 2 after the cesarean section (before she is discharged from the hospital). She will be informed about the project and invited to participate. As a potential project participant, she is entitled to a 24-hour consideration period, and if desired, a new contact will be arranged for the following day. If she wishes to participate, she will be contacted again after 3 months. At this time, she will receive a call to schedule a follow-up telephone interview within a few days. This will take place as a semi-structured interview, initiated with open questions and concluded with a few more specific questions. At the end of the interview, a screening for post-traumatic stress will be conducted using the PTSD-8 tool. Follow-up interviews will be recorded digitally and transcribed verbatim.\n\nSample Size The project encompasses all women at the participating centers who experience insufficient regional anesthesia during a cesarean section and conversion to general anesthesia during 1 year.",[26,293,294],"Cesarean Section Pain","Regional Anesthesia","2025-08-20",{"date":297,"type":32},"2025-08-27",{"date":299,"type":32},"2025-02-01",{"date":301,"type":20},"2027-01-01",{"name":303,"class":39},"Sygehus Lillebaelt",7,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":311,"maxAge":94,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":40},"100602994","effect-of-myofascial-release-versus-deep-friction-massage-on-abdominal-recovery-and-scar-after-cesarean-section-100602994","NCT07130747","Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section","Inclusion Criteria:\n\n1. All postpartum women \\>6 months postnatal having a post-Cesarean-section scar.\n2. Postpartum women with a well-healed cesarean section scar resulted in chronic pain in the scar, pelvis, or abdomen.\n3. Their ages will range from 30 to 45 years.\n4. Their body mass index (BMI) is less than 30 kg\u002Fm².\n\nExclusion Criteria:\n\n1. Pregnant women or planning for pregnancy.\n2. Postpartum women with abdominal infectious diseases.\n3. Cardiovascular diseases.\n4. Previous spinal surgery.\n5. History of skeletal deformity.\n6. Participation in any other exercise training program during this study.\n7. Malignant condition\n8. History of acute infection\n9. Neurological problem\n10. Mental problem to prevent evaluation and cooperation\n11. Having uncontrolled metabolic diseases like diabetes and thyroid disease","30 Years",{"count":313,"type":20},36,[23],"This study was done to compare the effect of myofascial release versus deep friction massage on abdominal recovery and scar after cesarean section.",[317,318,26,319],"Myofascial Release","Deep Friction Massage","Scar","2025-08-16",{"date":322,"type":32},"2025-08-19",{"date":324,"type":32},"2025-06-01",{"date":164,"type":20},{"name":327,"class":39},"Cairo University",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":40},"100457197","height-adjusted-versus-standardized-dose-of-bupivacaine-for-spinal-anesthesia-100457197","NCT05233462","Height Adjusted Versus Standardized Dose of Bupivacaine for Spinal Anesthesia","Height Adjusted Versus Standardized Dose of Bupivacaine in Spinal Anesthesia for Caesarean Delivery - A Randomized Double-blind Interventional Study","RAMCES","Inclusion Criteria:\n\n* scheduled cesarean section with intrathecal anesthesia\n* term pregnancy \\> 35 weeks\n* signed informed consent\n\nExclusion Criteria:\n\n* unscheduled or emergent cesarean section\n* any contra indication to intrathecal anesthesia\n* any antihypertensive drug prescribed to control arterial pressure during pregnancy\n* pre-eclampsia and eclampsia\n* history of Marfan or Ehlers Danlos disease",{"count":337,"type":20},250,[23],"General anesthesia during pregnancy is associated with several major risks including unanticipated difficult airway, pulmonary aspiration, and specific anesthetic effects on the newborn. Thus, intrathecal anesthesia is the technique of choice for cesarean section.\n\nNevertheless, the main side effect of intrathecal anesthesia is arterial hypotension which depend mainly on the dose of local anesthetic administered intrathecally.\n\nTo date there is no guidelines nor evidences whic help the anesthetist to precisely estimate the required dose. Most often a \"standardized dose\" of 8 to 10 mg of bupivacaine is administered. However, some data suggest that a lower dose may be administered resulting in less frequent arterial hypotension. Nevertheless, a well designed randomized study is lacking.",[341,26,342],"Regional Anesthesia Morbidity","Local Anesthetic Complication",[344,345,346,347],"cesarean section","intrathecal anesthesia","bupivacaine","morbidity","2025-07-22",{"date":350,"type":32},"2025-07-25",{"date":352,"type":32},"2022-02-23",{"date":354,"type":20},"2026-12-31",{"name":356,"class":39},"University Hospital, Caen",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":364,"targetDuration":4,"studyType":21,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":40},"100537945","durometer-for-measuring-uterine-tone-100537945","NCT06284421","Durometer for Measuring Uterine Tone","Use of a Durometer to Measure Uterine Tone in Cesarean Delivery","Inclusion Criteria:\n\n* Non-emergent (scheduled) cesarean delivery at University of Chicago Family Birth Center\n* Patients ages 18-50\n\nExclusion Criteria:\n\n* Patients undergoing unscheduled (intrapartum) cesarean delivery\n* Ages \\\u003C18 or \\>50 years old\n* Intrapartum cesarean hysterectomy\n* Inability to provide independent, informed consent due to impairment or intellectual disability\n* Non-English speaking patients",{"count":365,"type":20},20,[23],"This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery.",[369,26],"Uterine Tone Disorders","2025-05-05",{"date":372,"type":32},"2025-05-06",{"date":374,"type":32},"2024-02-08",{"date":376,"type":20},"2026-08-30",{"name":172,"class":39},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":21,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":407},"100500082","the-norwegian-world-health-organisation-labour-care-guide-trial-norwel-100500082","NCT05791630","The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)","The Norwegian World Health Organisation Labour Care Guide Trial","NORWEL","Inclusion Criteria:\n\n* Women in active labour\n* Labour and delivery at study sites\n\nExclusion Criteria:\n\n* None",{"count":387,"type":20},23650,[23],"Appropriate and timely care during birth is critical to the survival and health of women and their babies. In 2020, the World Health Organization (WHO) presented the Labour Care Guide (LCG) as the new recommended tool for monitoring birth and assessing progression, replacing the WHO partograph. This evidence-based guide was designed to ensure improved quality and safety of care, and to avoid unnecessary interventions during birth. The LCG was developed to be used in all settings globally, but it has only been tested in health facilities in South America, Asia and Africa, while it has not been tested in high-income settings. Implementing a new guideline for monitoring birth is a comprehensive operation that will affect both the national economy, health systems, and individual patients; therefore, further research on the possible advantages is needed before national enrolment. Hence, the trial proposed in this application is crucial to form the required foundation of knowledge. The trial will be conducted in labour wards at ten hospitals, covering all health regions in Norway, and the established Norwegian Research Network for Clinical Studies in Obstetrics (NORBIRTH), with dedicated local principal investigators, will provide a robust research environment. This trial will test the effect of the LCG. Results from this trial will provide knowledge needed to determine a future implementation of the LCG in Norway.",[391,392,393,394,395,396,26,397],"Labor Dystocia","Labor Complication","Labor Onset and Length Abnormalities","Labor (Obstetrics)--Complications","Experience, Life","Progression","Apgar; 4-7 at 1 Minute","2025-04-02",{"date":400,"type":32},"2025-04-04",{"date":402,"type":32},"2025-04-01",{"date":404,"type":20},"2030-12-31",{"name":406,"class":39},"Ostfold Hospital Trust",10,{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":180,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":21,"phases":417,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":40},"100516886","phase-3-comparing-intramyometrial-tranexamic-acid-and-oxytocin-for-blood-loss-in-cesarean-section-100516886","NCT06010368","Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section","The Effect of Intramyometrial Tranexamic Acid Versus Intramyometrial Oxytocin in Reducing Blood Loss During and After Elective Cesarean Section in Term Primigravida: A Double-blinded, Randomized, Comparative-placebo Trial","nclusion Criteria:\n\n* Women booked for a primary elective cesarean section, not in active labor\n* Aged between 20-40 years.\n* BMI 18.5-29.9 kg\u002F m2 pre-pregnancy weight\n* Term pregnancies (Early term: between 37 weeks, 0 days and 38 weeks, 6 days. Full term: between 39 weeks, 0 days and 40 weeks, 6 days. Late term: between 41 weeks, 0 days and 41 weeks, 6 days).\n* Singleton pregnancies.\n* Indication of elective cesarean section (Malpresentation, Malposition, Cephalopelvic disproportion, active herpes)\n* Fetal macrosomia (Macrosomia is defined as birth-weight over 4,000 g irrespective of gestational age)\n* Certain congenital fetal malformation and skeletal disorders (Several congenital anomalies are controversial indications for cesarean delivery; these include fetal neural tube defects (to avoid sac rupture), particularly defects that are larger than 5-6 cm in diameter as anterior cystic hygroma vascular sacrococcygeal teratoma, giant omphalocele and hydrocephalus with an enlarged biparietal diameter, and some skeletal dysplasia such as type III osteogenesis imperfecta. (Hamrick et al., 2008)\n\nExclusion Criteria:\n\n* Placenta previa.\n* Maternal hypertension and Preeclampsia.\n* Diabetes mellitus.\n* Severe medical disorder (renal or hepatic).\n* Multiple Fibroid uterus.\n* Multiple pregnancies.\n* Polyhydramnios.\n* Previous uterine surgery as myomectomy.\n* Contraindication to spinal anesthesia.\n* Blood coagulopathy and bleeding disorder.\n* Marked maternal anemia (Preoperative hemoglobin \\\u003C9 gm\u002Fdl).\n* Contraindications to TXA or oxytocin therapy (e.g. allergy)","40 Years",{"count":96,"type":20},[418],"PHASE3","Cesarean section is the most prevalent operation among women globally, 10-15% (1, 2). Recent research has shown Egypt to be the third-largest country globally, with an estimated 52% cesarean sections (3). However, the cesarean section has many serious complications, including the primary postpartum hemorrhage (PPH) (4). During labor, the average blood loss is about 300 to 400 ml. Bleeding postpartum is known as losing over five hundred milliliter of blood following a vaginal birth and losing over one thousand milliliter after the cesarean section (5). The prime cause of maternal death rate is postpartum bleeding, predominately in poor countries, and the estimated mortality number due to postpartum bleeding is one hundred thousand per year (6). Therefore, it is essential to reduce bleeding during and after CS to diminish maternal mortality and morbidity (7). The most successful technique for decreasing PPH is the active third stage labor management, requiring prophylactic uterotonic drugs like oxytocin, ergometrine malate, prostaglandins (E1, E2, and F2α), and combinations of them, or hemostatic agent as tranexamic acid (Kapron) and Etamsylate (Dicynon) (8, 9).",[26,421,158,155],"Tranexamic Acid","2024-09-02",{"date":424,"type":32},"2024-09-05",{"date":426,"type":20},"2024-10-01",{"date":428,"type":20},"2026-01-01",{"name":327,"class":39},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":21,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":40},"100539771","impact-of-single--versus-double-layer-hysterotomy-closure-on-cesarean-niche-development-a-randomized-controlled-trial-100539771","NCT06308172","Impact of Single- Versus Double-layer Hysterotomy Closure on Cesarean Niche Development: a Randomized Controlled Trial","Inclusion Criteria:\n\n* nulliparous\n* singleton\n* age 18-45\n* spontaneous pregnancy or autologous assisted fertilization\n* gestational age 38-40 weeks\n* elective C-section\n* informed consent\n\nExclusion Criteria:\n\n* coagulopathy\n* autoimmune diseases\n* gestational diabetes\n* anticoagulant therapy\n* immunosuppressive therapy\n* endometriosis\n* uterine fibromatosis\n* spontaneous labour\n* connective tissue diseases",{"count":96,"type":20},[23],"The objective of this randomized monocentric study is to assess potential variations in the incidence and severity of isthmocele morbidity among women undergoing cesarean section with either single or double-layer closure of the hysterotomy. Our primary outcome aims to investigate whether there is a reduction in the median duration of intermenstrual spotting in patients belonging to the two respective closure groups",[440,244,441,442,26],"Cesarean Section; Dehiscence","Uterus; Scar","Uterus Abnormal","2024-03-06",{"date":445,"type":32},"2024-03-13",{"date":447,"type":32},"2021-12-01",{"date":449,"type":20},"2026-12-01",{"name":451,"class":39},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"]